Furthermore, understanding the role of BRCA1/2 variants in ovarian cancer has allowed for the development of targeted therapies, namely PARP (poly[adenosine diphosphate–ribose] polymerase) inhibitors, which improve progression-free survival in selected women with ovarian cancer. The gene discussed is BRCA1; the disease is ovarian carcinoma.